Quick Answer
Arcadia Biosciences, Inc. reported Long-Term Debt of $0.00 for fiscal year 2021.
Arcadia Biosciences, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2021 | $0.00 | -100.0% |
| 2020 | $2.10M | +1867.3% |
| 2019 | $107.0K | -99.6% |
| 2016 | $25.13M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2021 | $78.0K | -96.9% | -10.3% |
| June 30, 2021 | $87.0K | -96.8% | -9.4% |
| March 31, 2021 | $96.0K | — | -95.4% |
| December 31, 2020 | $2.10M | +1867.3% | -17.4% |
| September 30, 2020 | $2.55M | — | -7.1% |
| June 30, 2020 | $2.74M | — | +2462.6% |
| December 31, 2019 | $107.0K | — | -99.5% |
| June 30, 2017 | $21.06M | — | -8.8% |
- Arcadia Biosciences, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Over the 2016–2021 period, Arcadia Biosciences, Inc.’s long-term debt has declined by 100.0% (from $25.13 million to $0.00).
- The most recent figure is from Arcadia Biosciences, Inc.’s fiscal year 2021 report (Form 10-K), filed with the SEC on March 31, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: